{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:22:02Z","timestamp":1761740522090,"version":"build-2065373602"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.sapharm.2014.06.001","type":"journal-article","created":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T12:48:47Z","timestamp":1402663727000},"page":"228-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Do depressed patients on adjunctive atypical antipsychotics demonstrate a better quality of life compared to those on antidepressants only? A comparative cross-sectional study of a nationally representative sample of the US population"],"prefix":"10.1016","volume":"11","author":[{"given":"Yazed Sulaiman","family":"Al-Ruthia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.sapharm.2014.06.001_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pds.2082","article-title":"Increasing off-label use of antipsychotic medications in the United States, 1995\u20132008","volume":"20","author":"Alexander","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.sapharm.2014.06.001_bib2","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1542\/peds.2011-2158","article-title":"Antipsychotics for children and young adults: a comparative effectiveness review","volume":"129","author":"Seida","year":"2012","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.sapharm.2014.06.001_bib3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00023210-200923050-00002","article-title":"Utility of atypical antipsychotics in the treatment of resistant unipolar depression","volume":"23","author":"DeBattista","year":"2009","journal-title":"CNS Drugs"},{"year":"2013","series-title":"Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications","author":"Stahl","key":"10.1016\/j.sapharm.2014.06.001_bib4"},{"issue":"1","key":"10.1016\/j.sapharm.2014.06.001_bib5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajp.158.1.131","article-title":"A novel augmentation strategy for treating resistant major depression","volume":"158","author":"Shelton","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"9","key":"10.1016\/j.sapharm.2014.06.001_bib6","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/sj.npp.1301131","article-title":"Report by the ACNP Task Force on response and remission in major depressive disorder","volume":"31","author":"Rush","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.sapharm.2014.06.001_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0193-953X(05)70283-5","article-title":"Definition and epidemiology of treatment-resistant depression","volume":"19","author":"Fava","year":"1996","journal-title":"Psychiatr Clin North Am"},{"issue":"11","key":"10.1016\/j.sapharm.2014.06.001_bib8","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"year":"2010","series-title":"Practice Guideline for the Treatment of Patients With Major Depressive Disorder","key":"10.1016\/j.sapharm.2014.06.001_bib9"},{"issue":"6","key":"10.1016\/j.sapharm.2014.06.001_bib10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4088\/JCP.v68n0602","article-title":"Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis","volume":"68","author":"Papakostas","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.sapharm.2014.06.001_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach","volume":"156","author":"McIntyre","year":"2014","journal-title":"J Affect Disord"},{"issue":"9","key":"10.1016\/j.sapharm.2014.06.001_bib12","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1176\/ps.2009.60.9.1175","article-title":"Off-label use of antipsychotic medications in the Department of Veterans Affairs health care system","volume":"60","author":"Leslie","year":"2009","journal-title":"Psychiatr Serv"},{"issue":"9","key":"10.1016\/j.sapharm.2014.06.001_bib13","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials","volume":"166","author":"Nelson","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"5 suppl B","key":"10.1016\/j.sapharm.2014.06.001_bib14","first-page":"1","article-title":"Summary of the comparative effectiveness review on off-label use of atypical antipsychotics","volume":"18","author":"Maher","year":"2012","journal-title":"J Manag Care Pharm"},{"year":"2010","series-title":"Second-generation Antipsychotics for Major Depressive Disorder and Dysthymia","author":"Komossa","key":"10.1016\/j.sapharm.2014.06.001_bib15"},{"issue":"3","key":"10.1016\/j.sapharm.2014.06.001_bib16","doi-asserted-by":"crossref","first-page":"e1001403","DOI":"10.1371\/journal.pmed.1001403","article-title":"Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes","volume":"10","author":"Spielmans","year":"2013","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.sapharm.2014.06.001_bib17","doi-asserted-by":"crossref","DOI":"10.3810\/pgm.2010.07.2174","article-title":"Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder","volume":"122","author":"Citrome","year":"2010","journal-title":"Postgrad Med"},{"issue":"11","key":"10.1016\/j.sapharm.2014.06.001_bib18","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1345\/aph.1M193","article-title":"Safety and efficacy of quetiapine in bipolar depression","volume":"43","author":"Bogart","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.sapharm.2014.06.001_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CEOR.S36526","article-title":"Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy","volume":"5","author":"Nadkarni","year":"2013","journal-title":"Clincoecon Outcomes Res"},{"issue":"9","key":"10.1016\/j.sapharm.2014.06.001_bib20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-147-9-200711060-00003","article-title":"Risperidone for treatment-refractory major depressive disorder. A randomized trial","volume":"147","author":"Mahmoud","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.sapharm.2014.06.001_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpsychires.2008.05.003","article-title":"A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression","volume":"43","author":"Keitner","year":"2009","journal-title":"J Psychiatr Res"},{"issue":"8","key":"10.1016\/j.sapharm.2014.06.001_bib22","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4088\/JCP.v69n0805","article-title":"Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study","volume":"69","author":"Reeves","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.sapharm.2014.06.001_bib23","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.4088\/JCP.v68n0714","article-title":"Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study","volume":"68","author":"Dunner","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.sapharm.2014.06.001_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1176\/ps.48.2.224","article-title":"Assessment of the quality of life of patients with major depression","volume":"48","author":"Pyne","year":"1997","journal-title":"Psychiatr Serv"},{"issue":"4","key":"10.1016\/j.sapharm.2014.06.001_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/11530230-000000000-00000","article-title":"Defining and measuring functional recovery from depression","volume":"24","author":"Greer","year":"2010","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.sapharm.2014.06.001_bib26","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1097\/00005650-198903001-00007","article-title":"The measurement of health status in clinical practice","volume":"27","author":"Nelson","year":"1989","journal-title":"Med Care"},{"year":"1997","series-title":"Measuring Quality of Life","key":"10.1016\/j.sapharm.2014.06.001_bib27"},{"issue":"5","key":"10.1016\/j.sapharm.2014.06.001_bib28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/10673229.2011.614099","article-title":"Quality of life: the ultimate outcome measure of interventions in major depressive disorder","volume":"19","author":"IsHak","year":"2011","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.sapharm.2014.06.001_bib29","doi-asserted-by":"crossref","unstructured":"Wells KB, Trust PM. The functioning and well-being of depressed patients: results from the Medical Outcomes Study 1989;262(7):914\u2013919.","DOI":"10.1001\/jama.1989.03430070062031"},{"issue":"suppl l","key":"10.1016\/j.sapharm.2014.06.001_bib30","first-page":"S23","article-title":"Quality of life: an important dimension in assessing the treatment of depression?","volume":"26","author":"Kennedy","year":"2001","journal-title":"J Psychiatry Neurosc"},{"issue":"1","key":"10.1016\/j.sapharm.2014.06.001_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.genhosppsych.2003.07.004","article-title":"Quality of life assessments in major depressive disorder: a review of the literature","volume":"26","author":"Papakostas","year":"2004","journal-title":"Gen Hosp Psychiatry"},{"issue":"11","key":"10.1016\/j.sapharm.2014.06.001_bib32","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.4088\/JCP.v67n1102","article-title":"A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder","volume":"67","author":"Shelton","year":"2006","journal-title":"J Clin Psychiatry"},{"year":"2008","series-title":"Sample Design of the Medical Expenditure Panel Survey Household Component, 1998-2007","author":"Ezzati-Rice","key":"10.1016\/j.sapharm.2014.06.001_bib33"},{"key":"10.1016\/j.sapharm.2014.06.001_bib34","unstructured":"Rockville M. Agency for Healthcare Research and Quality. US Department (2007)."},{"issue":"6","key":"10.1016\/j.sapharm.2014.06.001_bib35","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s11136-009-9483-1","article-title":"Reliability and validity of the SF-12v2 in the medical expenditure panel survey","volume":"18","author":"Cheak-Zamora","year":"2009","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.sapharm.2014.06.001_bib36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"issue":"11","key":"10.1016\/j.sapharm.2014.06.001_bib37","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0895-4356(98)00109-7","article-title":"Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment","volume":"51","author":"Gandek","year":"1998","journal-title":"J Clin Epidemiol"},{"year":"2012","series-title":"Trends in Use and Expenditures for Depression Among U.S. Adults Age 18 and Older, Civilian Noninstitutionalized Population, 1999 and 2009. STATISTICAL BRIEF# 377","author":"Soni","key":"10.1016\/j.sapharm.2014.06.001_bib38"},{"year":"2013","series-title":"Multum Lexicon Database. Cerner Multum","key":"10.1016\/j.sapharm.2014.06.001_bib39"},{"year":"2013","series-title":"National Drug Code Directory","key":"10.1016\/j.sapharm.2014.06.001_bib40"},{"issue":"5","key":"10.1016\/j.sapharm.2014.06.001_bib41","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.genhosppsych.2007.06.004","article-title":"Diagnostic accuracy of the mood module of the Patient Health Questionnaire: a systematic review","volume":"29","author":"Wittkampf","year":"2007","journal-title":"Gen Hosp Psychiatry"},{"issue":"5","key":"10.1016\/j.sapharm.2014.06.001_bib42","doi-asserted-by":"crossref","first-page":"e1097","DOI":"10.1542\/peds.2009-2712","article-title":"Evaluation of the PHQ-2 as a brief screen for detecting major depression among adolescents","volume":"125","author":"Richardson","year":"2010","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.sapharm.2014.06.001_bib43","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jad.2011.05.007","article-title":"Screening for depression with the Patient Health Questionnaire-2 (PHQ-2) among the general population in Hong Kong","volume":"134","author":"Yu","year":"2011","journal-title":"J Affect Disord"},{"issue":"11","key":"10.1016\/j.sapharm.2014.06.001_bib44","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/01.MLR.0000093487.78664.3C","article-title":"The Patient Health Questionnaire-2: validity of a two-item depression screener","volume":"41","author":"Kroenke","year":"2003","journal-title":"Med Care"},{"issue":"4","key":"10.1016\/j.sapharm.2014.06.001_bib45","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1532-5415.2007.01103.x","article-title":"Validity of the patient health questionnaire 2 (PHQ-2) in identifying major depression in older people","volume":"55","author":"Li","year":"2007","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"10.1016\/j.sapharm.2014.06.001_bib46","first-page":"1423","article-title":"Effective physician-patient communication and health outcomes: a review","volume":"152","author":"Stewart","year":"1995","journal-title":"CMAJ"},{"issue":"3","key":"10.1016\/j.sapharm.2014.06.001_bib47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.pec.2008.11.015","article-title":"How does communication heal? Pathways linking clinician\u2013patient communication to health outcomes","volume":"74","author":"Street","year":"2009","journal-title":"Patient Educ Couns"},{"issue":"1","key":"10.1016\/j.sapharm.2014.06.001_bib48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1471-6712.2008.00596.x","article-title":"Is satisfaction with doctors' care related to health-related quality of life, anxiety and depression among patients with carcinoid tumours? A longitudinal report","volume":"23","author":"Fr\u00f6jd","year":"2009","journal-title":"Scand J Caring Sci"},{"issue":"10","key":"10.1016\/j.sapharm.2014.06.001_bib49","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1525-1497.2005.0178.x","article-title":"A 2020 Vision of patient-centered primary care","volume":"20","author":"Davis","year":"2005","journal-title":"J Gen Intern Med"},{"year":"2013","series-title":"Access and Experiences Regarding Health Care: Estimates for the U.S. Civilian Noninstitutionalized Population Age 18 and Older, 2010","author":"Carroll","key":"10.1016\/j.sapharm.2014.06.001_bib50"},{"issue":"2","key":"10.1016\/j.sapharm.2014.06.001_bib51","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.arcmed.2004.12.009","article-title":"The impact of co-morbid conditions on the SF-36: a primary-care-based study among hypertensives","volume":"36","author":"Aydemir","year":"2005","journal-title":"Arch Med Res"},{"issue":"5","key":"10.1016\/j.sapharm.2014.06.001_bib52","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"6","key":"10.1016\/j.sapharm.2014.06.001_bib53","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.sapharm.2014.06.001_bib54","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0895-4356(02)00585-1","article-title":"How to measure comorbidity: a critical review of available methods","volume":"56","author":"de Groot","year":"2003","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.sapharm.2014.06.001_bib55","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jval.2013.01.006","article-title":"The mental component of the short-form 12 health survey (SF-12) as a measure of depressive disorders in the general population: results with three alternative scoring methods","volume":"16","author":"Vilagut","year":"2013","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.sapharm.2014.06.001_bib56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","article-title":"Side effects of atypical antipsychotics: a brief overview","volume":"7","author":"\u00dc\u00e7ok","year":"2008","journal-title":"World Psychiatry"},{"key":"10.1016\/j.sapharm.2014.06.001_bib57","series-title":"Issues in Clinical Psychology, Psychiatry, and Counseling: Scholarly Editions","article-title":"Electroconvulsive therapy","author":"Acton","year":"2012"},{"issue":"5","key":"10.1016\/j.sapharm.2014.06.001_bib58","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1472-8206.2003.00193.x","article-title":"Metabolic drug interactions with new psychotropic agents","volume":"17","author":"Spina","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.sapharm.2014.06.001_bib59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-199805000-00009","article-title":"Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia","volume":"13","author":"Spina","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.sapharm.2014.06.001_bib60","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-199408000-00011","article-title":"Elevated levels of clozapine in serum after addition of fluvoxamine","volume":"14","author":"Hiemke","year":"1994","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.sapharm.2014.06.001_bib61","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00007691-200108000-00015","article-title":"Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service","volume":"23","author":"Weigmann","year":"2001","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.sapharm.2014.06.001_bib62","doi-asserted-by":"crossref","DOI":"10.1017\/S1092852900020216","article-title":"Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants","volume":"14","author":"Berman","year":"2009","journal-title":"CNS Spectr"},{"issue":"6","key":"10.1016\/j.sapharm.2014.06.001_bib63","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/da.20130","article-title":"A randomized, double-blind comparison of olanzapine\/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression","volume":"23","author":"Corya","year":"2006","journal-title":"Depress Anxiety"},{"issue":"4","key":"10.1016\/j.sapharm.2014.06.001_bib64","first-page":"373","article-title":"The Medical Expenditure Panel Survey: a national health information resource","volume":"33","author":"Cohen","year":"1995","journal-title":"Inquiry"},{"issue":"9453","key":"10.1016\/j.sapharm.2014.06.001_bib65","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.sapharm.2014.06.001_bib66","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1192\/bjp.bp.108.051193","article-title":"Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action","volume":"195","author":"Harmer","year":"2009","journal-title":"Br J Psychiatry"},{"year":"2010","series-title":"National Depression Screening Day\u2014October 7, 2010","key":"10.1016\/j.sapharm.2014.06.001_bib67"},{"issue":"1","key":"10.1016\/j.sapharm.2014.06.001_bib68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1477-7525-3-51","article-title":"Subjective assessments of comorbidity correlate with quality of life health outcomes: initial validation of a comorbidity assessment instrument","volume":"3","author":"Bayliss","year":"2005","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1016\/j.sapharm.2014.06.001_bib69","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/appy.12103","article-title":"Validity and reliability of Patient Health Questionnaire-9 and Patient Health Questionnaire-2 to screen for depression among college students in China","volume":"5","author":"Zhang","year":"2013","journal-title":"Asia Pac Psychiatry"},{"issue":"4","key":"10.1016\/j.sapharm.2014.06.001_bib70","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.genhosppsych.2010.03.006","article-title":"The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review","volume":"32","author":"Kroenke","year":"2010","journal-title":"Gen Hosp Psychiatry"},{"issue":"3","key":"10.1016\/j.sapharm.2014.06.001_bib71","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/intqhc\/mzg032","article-title":"Indicators of quality of in-patient psychiatric treatment: the patients' view","volume":"15","author":"Langle","year":"2003","journal-title":"Int J Qual Health Care"},{"issue":"23","key":"10.1016\/j.sapharm.2014.06.001_bib72","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"J Am Med Assoc"},{"issue":"4","key":"10.1016\/j.sapharm.2014.06.001_bib73","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM199801223380401","article-title":"Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome","volume":"338","author":"Schmidt","year":"1998","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.sapharm.2014.06.001_bib74","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0006-3223(98)00162-0","article-title":"Estrogen\u2013serotonin interactions: implications for affective regulation","volume":"44","author":"Rubinow","year":"1998","journal-title":"Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.sapharm.2014.06.001_bib75","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1073\/pnas.0605569104","article-title":"Menstrual cycle phase modulates reward-related neural function in women","volume":"104","author":"Dreher","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.sapharm.2014.06.001_bib76","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1037\/0022-3514.77.5.1061","article-title":"Explaining the gender difference in depressive symptoms","volume":"77","author":"Nolen-Hoeksema","year":"1999","journal-title":"J Pers Soc Psychol"},{"issue":"1","key":"10.1016\/j.sapharm.2014.06.001_bib77","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2190\/PM.42.1.e","article-title":"Identification and treatment of depression in minority populations","volume":"42","author":"Dejesus","year":"2011","journal-title":"Int J Psychiatry Med"},{"year":"2013","series-title":"Health-related Quality of Life\u2014United States, 2006 and 2010","author":"Zack","key":"10.1016\/j.sapharm.2014.06.001_bib78"},{"issue":"3","key":"10.1016\/j.sapharm.2014.06.001_bib79","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.genhosppsych.2013.12.009","article-title":"Prevalence of depressive symptoms and predictors of treatment among US adults from 2005 to 2010","volume":"36","author":"Wittayanukorn","year":"2014","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"10.1016\/j.sapharm.2014.06.001_bib80","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00001199-199808000-00007","article-title":"The effect of employment on quality of life and community integration after traumatic brain injury","volume":"13","author":"O'Neill","year":"1998","journal-title":"J Head Trauma Rehabil"},{"issue":"4","key":"10.1016\/j.sapharm.2014.06.001_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1300\/J013v39n04_01","article-title":"Employment and quality of life outcomes among women with fibromyalgia compared to healthy controls","volume":"39","author":"Reisine","year":"2004","journal-title":"Women Health"},{"issue":"12","key":"10.1016\/j.sapharm.2014.06.001_bib82","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/da.20618","article-title":"The relationship between major depression and marital disruption is bidirectional","volume":"26","author":"Bulloch","year":"2009","journal-title":"Depress Anxiety"},{"issue":"9","key":"10.1016\/j.sapharm.2014.06.001_bib83","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00127-009-0130-5","article-title":"A comparison of quality of life and depression between female married immigrants and native married women in Taiwan","volume":"45","author":"Chou","year":"2010","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"10.1016\/j.sapharm.2014.06.001_bib84","unstructured":"Using antipsychotics to treat: depression comparing effectiveness, safety, and price. Consumer Reports Health Best Buy Drugs 2011;1\u201314. Available at: http:\/\/www.consumerreports.org\/health\/best-buy-drugs\/antipsychotics-for-depression.htm."},{"issue":"2","key":"10.1016\/j.sapharm.2014.06.001_bib85","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jpsychores.2004.09.006","article-title":"Detecting and monitoring depression with a two-item questionnaire (PHQ-2)","volume":"58","author":"L\u00f6we","year":"2005","journal-title":"J Psychosom Res"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741114000710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741114000710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:10:28Z","timestamp":1761556228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741114000710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1551741114000710"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2014.06.001","relation":{},"ISSN":["1551-7411"],"issn-type":[{"type":"print","value":"1551-7411"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do depressed patients on adjunctive atypical antipsychotics demonstrate a better quality of life compared to those on antidepressants only? A comparative cross-sectional study of a nationally representative sample of the US population","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2014.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}